A novel low-cost assay sequencing cell-free DNA methylome in blood demonstrates strong performance across a range of clinical applications.
Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...
Researchers from Wageningen University & Research and Van Andel Institute used a variant of CRISPR, a gene-editing tool, to ...
A new study suggests that a single blood sample could soon detect multiple cancers, including liver, stomach, and lung cancer ...
Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
TRIM28-mediated SUMOylation of ERG at K389 and its association with cell proliferation, PARP inhibitor response, and 53BP1 expression in castration-resistant prostate cancer. Heterogeneity and ...
Detection Market · GlobeNewswire Inc. The cell-free tumor DNA detection market is set to experience significant growth, expanding from $2.58 billion in 2025 to $3.02 billion in 2026 at a CAGR of 17.2% ...
When Erica Barnell was an MD/PhD student at Washington University in St. Louis, she met a woman who had stage four colorectal cancer (CRC). The woman was only 52 years old—more than a decade younger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results